Henry Meds
Editorial reviewA flat-fee compounded pioneer — simple model, but priced at the higher end now.
Visit Henry MedsHead-to-head verdict
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, no pay-to-win placement.
A flat-fee compounded pioneer — simple model, but priced at the higher end now.
Visit Henry MedsThe most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxCoreAge Rx takes it with a higher Verdict Score — 94/100 to 84/100 (grade A vs B). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Henry Meds still earns its place — people who want a simple, well-known flat-fee compounded program.
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
| Metric | Henry Meds | CoreAge Rx |
|---|---|---|
| Verdict Score | 84/100 | 94/100 |
| Grade | B | A |
| Semaglutide | $249/mo | $149/mo |
| Tirzepatide | $349/mo | $349/mo |
| Coverage | Multi-state | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
| Relationship | Editorial | Partner |
What we like
The caveats
What we like
The caveats
Also worth a look
People who want a simple, well-known flat-fee compounded program.
Visit Henry Meds Read the full Henry Meds review →Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.